直近一年間の累計
アクセス数 : ?
ダウンロード数 : ?
ID 118971
著者
板東, 浩 Tokushima University|Medical Research KAKEN研究者をさがす
キーワード
Astaxanthin
Anti-aging medicine
oral hypoglycemic agent
Imeglimin
資料タイプ
学術雑誌論文
抄録
Latest Standards of Medical Care in Diabetes-2022 was presented from American Diabetes Association (ADA) on Jan 2022. A topic of Oral Hypoglycemic Agent (OHA) has been imeglimin. It may work through multiple action mechanism such as increasing insulin secretion, decreasing β-cell dysfunction, and preventing death of epithelial cells. Clinically, it decreases HbA1c by 0.5-1.0% for 1000mg twice a day. Diabetes and anti-aging medicine have common background pathophysiologically. Astaxanthin (AX) is the nephroprotective as mitochondrial regulator. AX-functioning mechanism includes to ameliorate insulin resistance and glucose intolerance. Imeglimin normalizes insulin sensitivity and glucose tolerance with maintaining mitochondrial function, suggesting common mechanism.
掲載誌名
Edelweiss Journal of Biomedical Research and Review
ISSN
26902613
出版者
Edelweiss Publications
4
1
開始ページ
1
終了ページ
2
発行日
2022-06-23
権利情報
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
出版社版DOI
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
医学系